M
Marjorie McMeniman
Researcher at Albert Einstein College of Medicine
Publications - 11
Citations - 1594
Marjorie McMeniman is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Schizophrenia & Brief Psychiatric Rating Scale. The author has an hindex of 10, co-authored 11 publications receiving 1524 citations. Previous affiliations of Marjorie McMeniman include University of Minnesota & North Shore-LIJ Health System.
Papers
More filters
Journal ArticleDOI
Symptomatic and Functional Recovery From a First Episode of Schizophrenia or Schizoaffective Disorder
TL;DR: Although some patients with first-episode schizophrenia can achieve sustained symptomatic and functional recovery, the overall rate of recovery during the early years of the illness is low.
Journal ArticleDOI
Brain Structural Abnormalities in Psychotropic Drug-Naive Pediatric Patients With Obsessive-Compulsive Disorder
Philip R. Szeszko,Shauna MacMillan,Marjorie McMeniman,Steven Xi Chen,Keith Baribault,Kelvin O. Lim,Jennifer Ivey,Michelle Rose,S. Preeya Banerjee,Rashmi P. Bhandari,Gregory J. Moore,David R. Rosenberg +11 more
TL;DR: Volumetric abnormalities in the anterior cingulate gyrus appear specific to the gray matter in OCD, at least at the gross anatomic level, and are consistent with findings of functional neuroimaging studies that have reported anterior cedulate hypermetabolism in the disorder.
Journal ArticleDOI
Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
John M. Kane,Stephen R. Marder,Nina R. Schooler,William C. Wirshing,Daniel Umbricht,Robert W. Baker,Donna A. Wirshing,Allan Z. Safferman,Rohan Ganguli,Marjorie McMeniman,Michael Borenstein +10 more
TL;DR: Compared with a first-generation antipsychotic given in a moderate dose, clozapine offers substantial clinical benefits to treatment-refractory subjects who can be treated in the community andvantages are seen in a broad range of symptoms but do not extend to negative symptoms.
Journal ArticleDOI
Early Prediction of Antipsychotic Response in Schizophrenia
TL;DR: Patients with minimal improvement in positive symptoms during the first week of treatment with a typical antipsychotic are unlikely to respond to a 4-week trial, and data require confirmation and extension to studies with second-generation antipsychotics.
Journal ArticleDOI
Reduced frontal white matter integrity in early-onset schizophrenia: a preliminary study.
Sanjiv Kumra,Sanjiv Kumra,Manzar Ashtari,Manzar Ashtari,Marjorie McMeniman,Marjorie McMeniman,Joshua Vogel,Joshua Vogel,Rachel Augustin,Rachel Augustin,David E. Becker,David E. Becker,Emilie Nakayama,Emilie Nakayama,Kunsang Gyato,Kunsang Gyato,John M. Kane,John M. Kane,Kelvin O. Lim,Kelvin O. Lim,Philip R. Szeszko,Philip R. Szeszko +21 more
TL;DR: The preliminary data support a hypothesis that alterations in brain WM integrity occur in adolescents with EOS, and abnormalities found in this study were similar to those reported in adults with chronic schizophrenia.